A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 219 participants.

Also called NCT04233801

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 219 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04233801
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04233801. Randomized; triple masking; primary purpose treatment. Start 2020-04-15 (actual); primary completion 2022-03-03 (actual). Results posted on 2023-12-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Empagliflozin
Intervention (Drug)
Placebo
Lead sponsor
Boehringer Ingelheim (class: industry)

Record details

Record id
cardio:ct-nct04233801
Content hash
a2e7aa18d77fc9636b99f1ce0d314e8133c2858d228096fccc6e6febe79627df